JPWO2021011496A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021011496A5
JPWO2021011496A5 JP2022502029A JP2022502029A JPWO2021011496A5 JP WO2021011496 A5 JPWO2021011496 A5 JP WO2021011496A5 JP 2022502029 A JP2022502029 A JP 2022502029A JP 2022502029 A JP2022502029 A JP 2022502029A JP WO2021011496 A5 JPWO2021011496 A5 JP WO2021011496A5
Authority
JP
Japan
Prior art keywords
cancer
composition
construct
immunotherapeutic
immunotherapeutic construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502029A
Other languages
Japanese (ja)
Other versions
JP2022540867A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041844 external-priority patent/WO2021011496A1/en
Publication of JP2022540867A publication Critical patent/JP2022540867A/en
Publication of JPWO2021011496A5 publication Critical patent/JPWO2021011496A5/ja
Pending legal-status Critical Current

Links

Description

本明細書において、提供される免疫療法構築物の態様のいずれか、およびそのような構築物を使用する方法の態様は、免疫療法構築物が腫瘍特異的抗原またはオボアルブミンを含まない例を含むことが特に企図される。
[本発明1001]
腫瘍抗原放出を引き起こすおよび/または免疫抑制性腫瘍微小環境を調節する少なくとも1つの治療剤と、少なくとも1つのアジュバントとを含む、送達システム
を含む、免疫療法構築物であって、
腫瘍特異的抗原またはオボアルブミンを含まない、前記免疫療法構築物。
[本発明1002]
送達システムが、リポソーム、脂質系粒子、ポリマー粒子、無機粒子、またはそれらのハイブリッドを含む、本発明1001の免疫療法構築物。
[本発明1003]
送達ビヒクルが、リポソーム、脂質系粒子、ポリマー粒子、無機粒子、またはポリマーもしくは脂質で被覆された無機粒子である、本発明1002の免疫療法構築物。
[本発明1004]
送達ビヒクルが、無機粒子であり、メソポーラスシリカ、金、アルミニウム、銀、酸化鉄、リン酸カルシウム、または抗酸化剤粒子のうちの1つまたは複数を含む、本発明1003の免疫療法構築物。
[本発明1005]
無機粒子が、酸化セリウムを含む抗酸化剤粒子を含む、本発明1004の免疫療法構築物。
[本発明1006]
送達ビヒクルが、メソポーラスシリカ粒子を含む、本発明1004の免疫療法構築物。
[本発明1007]
送達ビヒクルが、フラーレン、エンドヘドラル金属フラーレン（endohedral metallofullerene）、三金属窒化物鋳型エンドヘドラル金属フラーレン、単層カーボンナノチューブおよび多層カーボンナノチューブ、分枝状カーボンナノチューブおよび樹枝状カーボンナノチューブ、金ナノロッド、銀ナノロッド、単層ホウ素/ナイトレートナノチューブおよび多層ホウ素/ナイトレートナノチューブ、カーボンナノチューブピーポッド、カーボンナノホーン、カーボンナノホーンピーポッド、リポソーム、ナノシェル、デンドリマー、マイクロ粒子、量子ドット、超常磁性ナノ粒子、ナノロッド、セルロースナノ粒子、ケイ素、シリカマイクロスフェアおよびシリカナノスフェア、ポリマーマイクロスフェアおよびポリマーナノスフェア、シリカシェル、生分解性PLGAマイクロスフェアおよび生分解性PLGAナノスフェア、金粒子、酸化セリウム粒子、酸化亜鉛粒子、銀粒子、アルミニウム粒子、炭素粒子、鉄粒子、酸化鉄粒子、アジュバント粒子、ならびに/または修飾ミセルのうちの1つまたは複数を含む、本発明1001の免疫療法構築物。
[本発明1008]
送達ビヒクルが、PLGA、PLL、デキストラン、デンドリマー、ポリアルギニン、PEG、PEI、またはキトサンのうちの1つまたは複数を含むポリマー粒子である、本発明1001～1007のいずれかの免疫療法構築物。
[本発明1009]
5nm～999nmの流体力学的サイズを有する、本発明1001～1008のいずれかの免疫療法構築物。
[本発明1010]
1ミクロン～1000ミクロンの流体力学的サイズを有する、本発明1001～1008のいずれかの免疫療法構築物。
[本発明1011]
送達ビヒクルが、約5～約200nmのサイズを有するメソポーラスシリカナノ粒子を含む、本発明1006の免疫療法構築物。
[本発明1012]
メソポーラスシリカナノ粒子が、架橋されたポリエチレンイミンおよびポリエチレングリコールで被覆されている、本発明1011の免疫療法構築物。
[本発明1013]
少なくとも1つの治療剤が、siRNA、miRNA、アンチセンスオリゴヌクレオチド、mRNA、DNA、sgRNA（CRISPR-cas9エレメント）、オリゴヌクレオチド、ポリヌクレオチド、ペプチド、タンパク質、化学療法薬、毒素、抗酸化剤、小分子阻害剤、抗体、または放射線療法剤を含む、本発明1001～1012のいずれかの免疫療法構築物。
[本発明1014]
少なくとも1つの治療剤が、siRNA、miRNA、アンチセンスオリゴヌクレオチド、mRNA、またはDNAを含む、本発明1013の免疫療法構築物。
[本発明1015]
少なくとも1つの治療剤が、siRNAを含む、本発明1014の免疫療法構築物。
[本発明1016]
少なくとも1つの治療剤が、STAT3、CD39、CD73、TGF-β、PD-L1、PD1、CTLA4、MIF、PLK1、HIF、NOX1～4、HER2、EGFR、BCL2、AKT1、HIF1-α、NOX1～4、AR、MYC、BRAF、BRAF V600E、またはMTDHの発現または活性を阻害するsiRNAを含む、本発明1015の免疫療法構築物。
[本発明1017]
少なくとも1つの治療剤が、STAT3の発現または活性を阻害するsiRNAを含む、本発明1015または1016の免疫療法構築物。
[本発明1018]
少なくとも1つの治療剤が、HER2の活性の発現を阻害するsiRNAを含む、本発明1015～1017のいずれかの免疫療法構築物。
[本発明1019]
少なくとも1つの治療剤が、STAT3、CD39、CD73、TGF-β、PD-L1、PD1、CTLA4、MIF、PLK1、HIF、NOX1～4、HER2、EGFR、BCL2、AKT1、HIF1-α、NOX1～4、AR、MYC、BRAF、BRAF V600E、またはMTDHの発現または活性を阻害する、本発明1001～1012のいずれかの免疫療法構築物。
[本発明1020]
少なくとも1つの治療剤が、抗生物質、植物アルカロイド、PLK1阻害剤、分裂期キナーゼ阻害剤、免疫チェックポイント阻害剤、白金系化学療法剤、HER2小分子阻害剤、抗EGFR抗体、および抗HER2抗体から選択される1つまたは複数の抗癌剤を含む、本発明1001～1019のいずれかの免疫療法構築物。
[本発明1021]
少なくとも1つの治療剤が、免疫チェックポイント阻害剤を含み、免疫チェックポイント阻害剤が、PD-L1、PD1、またはCTLA4に対する抗体である、本発明1020の免疫療法構築物。
[本発明1022]
免疫チェックポイント阻害剤が、PD-L1に対する抗体である、本発明1021の免疫療法構築物。
[本発明1023]
少なくとも1つの治療剤が、PLK1阻害剤を含む、本発明1001～1022のいずれかの免疫療法構築物。
[本発明1024]
PLK1阻害剤がボラセルチブである、本発明1023の免疫療法構築物。
[本発明1025]
少なくとも1つの治療剤が、ドセタキセル、ミトキサントロン、またはカバジタキセルのうちの1つまたは複数を含む、本発明1001～1024のいずれかの免疫療法構築物。
[本発明1026]
少なくとも1つの治療剤が、抗EGFR抗体を含む、本発明1001～1025のいずれかの免疫療法構築物。
[本発明1027]
抗EGFR抗体がセツキシマブである、本発明1026の免疫療法構築物。
[本発明1028]
少なくとも1つの治療剤が、抗HER2抗体を含む、本発明1001～1025のいずれかの免疫療法抗体。
[本発明1029]
抗HER2抗体がトラスツズマブである、本発明1028の免疫療法抗体。
[本発明1030]
アジュバントが、免疫刺激活性を有し、CpGオリゴヌクレオチド、CpG配列を含むDNA TLRアゴニスト、非CpG DNA TLRアゴニスト、RNA TLRアゴニスト、アルミニウム塩、抗CD40抗体、融合タンパク質、サイトカイン、小分子TLRアゴニスト、油系アジュバントもしくは界面活性剤系アジュバント、リポ多糖、植物抽出物、またはそれらの誘導体のうちの1つまたは複数を含む、本発明1001～1029のいずれかの免疫療法構築物。
[本発明1031]
アジュバントが、CpGオリゴヌクレオチド、イミキモド、レシキモド、ガーディキモド、ポリI:C、ポリICLC、dSLIM、またはEnanDIMを含む、本発明1001～1030のいずれかの免疫療法構築物。
[本発明1032]
アジュバントが、CpGオリゴヌクレオチドを含む、本発明1001～1031のいずれかの免疫療法構築物。
[本発明1033]
本発明1001～1032のいずれかの免疫療法構築物と、
少なくとも1つの薬学的に許容される担体、賦形剤、希釈剤、またはそれらの混合物と
を含む、組成物。
[本発明1034]
癌を有する対象に、本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の有効量を投与する工程を含む、癌を処置する方法。
[本発明1035]
対象が哺乳動物である、本発明1034の方法。
[本発明1036]
哺乳動物がヒトである、本発明1035の方法。
[本発明1037]
癌の症状を示す細胞を処置する方法であって、
該細胞と、本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の治療有効量とを接触させる工程
を含む、前記方法。
[本発明1038]
癌または別の過剰増殖性障害の症状を示す対象から得られた細胞を処置する方法であって、
該細胞と、本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の治療有効量とを接触させる工程
を含む、前記方法。
[本発明1039]
癌または別の過剰増殖性障害の症状を示す対象から得られた細胞を処置する方法であって、
細胞と、本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の治療有効量とをエクスビボで接触させる工程
を含む、前記方法。
[本発明1040]
細胞が癌細胞である、本発明1038または1039の方法。
[本発明1041]
細胞が癌細胞ではない、本発明1038または1039の方法。
[本発明1042]
細胞が免疫細胞である、本発明1041の方法。
[本発明1043]
細胞が不死化される、本発明1038または1039の方法。
[本発明1044]
少なくとも1つの処置された細胞を対象に戻すように投与する工程をさらに含む、本発明1037～1043のいずれかの方法。
[本発明1045]
過剰増殖性疾患もしくは過剰増殖性病態を有すると診断されたかまたはそのような疾患もしくは病態を発症するリスクが高いと診断された対象を処置する方法であって、
本発明1033の組成物の有効量を該対象に投与する工程
を含む、前記方法。
[本発明1046]
対象が哺乳動物である、本発明1045の方法。
[本発明1047]
哺乳動物がヒトである、本発明1046の方法。
[本発明1048]
過剰増殖性疾患または過剰増殖性病態が、癌、前癌、または癌転移のうちの1つまたは複数を含む、本発明1045～1047のいずれかの方法。
[本発明1049]
過剰増殖性疾患が、黒色腫、肺癌、乳癌、膵癌、脳癌、前立腺癌、頭頸部癌、腎癌、結腸直腸癌、リンパ腫、胃癌、結腸癌、肝癌、または稀な癌のうちの1つまたは複数を含む、本発明1045～1048のいずれかの方法。
[本発明1050]
投与する工程が、
対象の腫瘍への、もしくは対象の腫瘍での注射、
対象の腫瘍への、もしくは対象の腫瘍での局所的な注入、
対象における全身注射、
対象における全身注入、または
対象への局所適用
を含む、本発明1045～1049のいずれかの方法。
[本発明1051]
投与工程が、対象へのマイクロニードル適用を含む、本発明1045～1050のいずれかの方法。
[本発明1052]
それを必要とする対象において抗癌療法の効果を増強する方法であって、
本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の有効量と、
少なくとも1つの抗癌剤と
をそれを必要とする対象に投与する工程
を含む、前記方法。
[本発明1053]
抗癌剤が、化学療法剤または標的療法剤である、本発明1052の方法。
[本発明1054]
新生物を有すると診断された対象においてチェックポイント遮断免疫療法の効果を増強する方法であって、
本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の有効量と、
少なくとも1つの免疫チェックポイント阻害剤と
をそれを必要とする対象に投与する工程
を含む、前記方法。
[本発明1055]
新生物を有すると診断された対象において放射線療法の効果を増強する方法であって、
本発明1001～1032のいずれかの免疫療法構築物または本発明1033の組成物の有効量と、
少なくとも1つの放射線療法と
をそれを必要とする対象に投与する工程
を含む、前記方法。
[本発明1056]
免疫療法構築物または組成物と抗癌療法とが、連続的にまたは同時に投与される、本発明1052～1055のいずれかの方法。
[本発明1057]
対象が哺乳動物である、本発明1052～1056のいずれかの方法。
[本発明1058]
哺乳動物がヒトである、本発明1057の方法。
[本発明1059]
本発明1001～1032のいずれかの免疫療法構築物と、
少なくとも1つの抗癌剤と
を含む、キット。
[本発明1060]
抗癌剤が、化学療法剤、標的療法剤、または免疫チェックポイント阻害剤である、本発明1059のキット。 Any of the embodiments of immunotherapeutic constructs provided herein, and the embodiments of methods of using such constructs, specifically include instances where the immunotherapeutic construct does not include a tumor-specific antigen or ovalbumin. planned.
[Invention 1001]
A delivery system comprising at least one therapeutic agent that causes tumor antigen release and/or modulates an immunosuppressive tumor microenvironment and at least one adjuvant.
An immunotherapy construct comprising:
Said immunotherapeutic construct does not contain tumor-specific antigens or ovalbumin.
[Present invention 1002]
The immunotherapeutic construct of the invention 1001, wherein the delivery system comprises a liposome, a lipid-based particle, a polymeric particle, an inorganic particle, or a hybrid thereof.
[Present invention 1003]
The immunotherapeutic construct of the invention 1002, wherein the delivery vehicle is a liposome, a lipid-based particle, a polymeric particle, an inorganic particle, or an inorganic particle coated with a polymer or lipid.
[Present invention 1004]
The immunotherapeutic construct of the invention 1003, wherein the delivery vehicle is an inorganic particle and includes one or more of mesoporous silica, gold, aluminum, silver, iron oxide, calcium phosphate, or antioxidant particles.
[Present invention 1005]
The immunotherapeutic construct of the present invention 1004, wherein the inorganic particles include antioxidant particles that include cerium oxide.
[Present invention 1006]
The immunotherapeutic construct of the invention 1004, wherein the delivery vehicle comprises mesoporous silica particles.
[Present invention 1007]
The delivery vehicle may include fullerenes, endohedral metallofullerenes, trimetal nitride-templated endohedral metallofullerenes, single- and multi-walled carbon nanotubes, branched and dendritic carbon nanotubes, gold nanorods, silver nanorods, single layered boron/nitrate nanotubes and multiwalled boron/nitrate nanotubes, carbon nanotube peapods, carbon nanohorns, carbon nanohorn peapods, liposomes, nanoshells, dendrimers, microparticles, quantum dots, superparamagnetic nanoparticles, nanorods, cellulose nanoparticles, silicon, Silica microspheres and silica nanospheres, polymer microspheres and polymer nanospheres, silica shells, biodegradable PLGA microspheres and biodegradable PLGA nanospheres, gold particles, cerium oxide particles, zinc oxide particles, silver particles, aluminum particles, carbon particles, The immunotherapeutic construct of the invention 1001, comprising one or more of iron particles, iron oxide particles, adjuvant particles, and/or modified micelles.
[Present invention 1008]
The immunotherapeutic construct of any of the inventions 1001-1007, wherein the delivery vehicle is a polymeric particle comprising one or more of PLGA, PLL, dextran, dendrimer, polyarginine, PEG, PEI, or chitosan.
[Present invention 1009]
The immunotherapeutic construct of any of the invention 1001-1008, having a hydrodynamic size of 5 nm to 999 nm.
[Present invention 1010]
The immunotherapeutic construct of any of the invention 1001-1008, having a hydrodynamic size of 1 micron to 1000 microns.
[Present invention 1011]
The immunotherapeutic construct of the invention 1006, wherein the delivery vehicle comprises mesoporous silica nanoparticles having a size of about 5 to about 200 nm.
[Invention 1012]
The immunotherapeutic construct of the invention 1011, wherein mesoporous silica nanoparticles are coated with cross-linked polyethyleneimine and polyethylene glycol.
[Present invention 1013]
At least one therapeutic agent is siRNA, miRNA, antisense oligonucleotide, mRNA, DNA, sgRNA (CRISPR-cas9 element), oligonucleotide, polynucleotide, peptide, protein, chemotherapeutic drug, toxin, antioxidant, small molecule The immunotherapeutic construct of any of the invention 1001-1012, comprising an inhibitor, antibody, or radiotherapeutic agent.
[Present invention 1014]
The immunotherapeutic construct of the invention 1013, wherein at least one therapeutic agent comprises siRNA, miRNA, antisense oligonucleotide, mRNA, or DNA.
[Present invention 1015]
The immunotherapeutic construct of the invention 1014, wherein at least one therapeutic agent comprises siRNA.
[Invention 1016]
At least one therapeutic agent is STAT3, CD39, CD73, TGF-β, PD-L1, PD1, CTLA4, MIF, PLK1, HIF, NOX1-4, HER2, EGFR, BCL2, AKT1, HIF1-α, NOX1-4 , AR, MYC, BRAF, BRAF V600E, or MTDH.
[Invention 1017]
The immunotherapeutic construct of the invention 1015 or 1016, wherein at least one therapeutic agent comprises siRNA that inhibits STAT3 expression or activity.
[Invention 1018]
The immunotherapeutic construct of any of the inventions 1015-1017, wherein the at least one therapeutic agent comprises siRNA that inhibits expression of HER2 activity.
[Invention 1019]
At least one therapeutic agent is STAT3, CD39, CD73, TGF-β, PD-L1, PD1, CTLA4, MIF, PLK1, HIF, NOX1-4, HER2, EGFR, BCL2, AKT1, HIF1-α, NOX1-4 , AR, MYC, BRAF, BRAF V600E, or MTDH.
[Invention 1020]
At least one therapeutic agent is selected from the group consisting of antibiotics, plant alkaloids, PLK1 inhibitors, mitotic kinase inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy agents, HER2 small molecule inhibitors, anti-EGFR antibodies, and anti-HER2 antibodies. The immunotherapeutic construct of any of the invention 1001-1019, comprising one or more selected anti-cancer agents.
[Invention 1021]
The immunotherapeutic construct of the invention 1020, wherein at least one therapeutic agent comprises an immune checkpoint inhibitor, and the immune checkpoint inhibitor is an antibody against PD-L1, PD1, or CTLA4.
[Invention 1022]
The immunotherapeutic construct of the invention 1021, wherein the immune checkpoint inhibitor is an antibody against PD-L1.
[Invention 1023]
The immunotherapeutic construct of any of the inventions 1001-1022, wherein at least one therapeutic agent comprises a PLK1 inhibitor.
[Invention 1024]
The immunotherapeutic construct of the invention 1023, wherein the PLK1 inhibitor is volasertib.
[Invention 1025]
The immunotherapeutic construct of any of the inventions 1001-1024, wherein the at least one therapeutic agent comprises one or more of docetaxel, mitoxantrone, or cabazitaxel.
[Invention 1026]
The immunotherapeutic construct of any of the inventions 1001-1025, wherein at least one therapeutic agent comprises an anti-EGFR antibody.
[Invention 1027]
The immunotherapeutic construct of the invention 1026, wherein the anti-EGFR antibody is cetuximab.
[Invention 1028]
The immunotherapeutic antibody of any of the inventions 1001-1025, wherein at least one therapeutic agent comprises an anti-HER2 antibody.
[Invention 1029]
The immunotherapeutic antibody of the invention 1028, wherein the anti-HER2 antibody is trastuzumab.
[Invention 1030]
The adjuvant has immunostimulatory activity, CpG oligonucleotides, DNA TLR agonists containing CpG sequences, non-CpG DNA TLR agonists, RNA TLR agonists, aluminum salts, anti-CD40 antibodies, fusion proteins, cytokines, small molecule TLR agonists, oils. The immunotherapeutic construct of any of the inventions 1001-1029, comprising one or more of a surfactant-based adjuvant, a lipopolysaccharide, a plant extract, or a derivative thereof.
[Present invention 1031]
The immunotherapeutic construct of any of the invention 1001-1030, wherein the adjuvant comprises a CpG oligonucleotide, imiquimod, resiquimod, gardikimod, poly I:C, poly ICLC, dSLIM, or EnanDIM.
[Invention 1032]
The immunotherapeutic construct of any of the invention 1001-1031, wherein the adjuvant comprises a CpG oligonucleotide.
[Present invention 1033]
The immunotherapeutic construct of any of the invention 1001-1032;
at least one pharmaceutically acceptable carrier, excipient, diluent, or mixture thereof;
A composition comprising.
[Present invention 1034]
A method of treating cancer comprising administering to a subject having cancer an effective amount of an immunotherapeutic construct of any of the inventions 1001-1032 or a composition of the invention 1033.
[Invention 1035]
1034. The method of the invention, wherein the subject is a mammal.
[Invention 1036]
1035. The method of the invention 1035, wherein the mammal is a human.
[Present invention 1037]
A method of treating cells exhibiting symptoms of cancer, the method comprising:
contacting the cell with a therapeutically effective amount of an immunotherapeutic construct of any of the inventions 1001-1032 or a composition of the invention 1033.
The method described above.
[Invention 1038]
A method of treating cells obtained from a subject exhibiting symptoms of cancer or another hyperproliferative disorder, the method comprising:
contacting the cell with a therapeutically effective amount of an immunotherapeutic construct of any of the inventions 1001-1032 or a composition of the invention 1033.
The method described above.
[Invention 1039]
A method of treating cells obtained from a subject exhibiting symptoms of cancer or another hyperproliferative disorder, the method comprising:
Contacting the cells ex vivo with a therapeutically effective amount of an immunotherapeutic construct of any of the inventions 1001-1032 or a composition of the invention 1033
The method described above.
[Invention 1040]
The method of the invention 1038 or 1039, wherein the cell is a cancer cell.
[Present invention 1041]
1038 or 1039 of the method of the invention, wherein the cell is not a cancer cell.
[Present invention 1042]
1041. The method of the invention 1041, wherein the cell is an immune cell.
[Invention 1043]
A method according to the invention 1038 or 1039, wherein the cells are immortalized.
[Present invention 1044]
The method of any of the inventions 1037-1043, further comprising administering at least one treated cell back to the subject.
[Invention 1045]
A method of treating a subject who has been diagnosed with a hyperproliferative disease or condition or who has been diagnosed with an increased risk of developing such a disease or condition, the method comprising:
Administering an effective amount of the composition of the present invention 1033 to the subject
The method described above.
[Invention 1046]
1045. The method of the invention, wherein the subject is a mammal.
[Invention 1047]
1046. The method of the invention, wherein the mammal is a human.
[Invention 1048]
The method of any of the inventions 1045-1047, wherein the hyperproliferative disease or hyperproliferative condition comprises one or more of cancer, pre-cancer, or cancer metastasis.
[Invention 1049]
The hyperproliferative disease is one of the following: melanoma, lung cancer, breast cancer, pancreatic cancer, brain cancer, prostate cancer, head and neck cancer, kidney cancer, colorectal cancer, lymphoma, stomach cancer, colon cancer, liver cancer, or rare cancers or more.
[Invention 1050]
The process of administering
injection into or at the target tumor;
local injection into or at the tumor of interest;
systemic injection in the subject,
systemic injection in the subject, or
Local application to target
The method of any of inventions 1045-1049, comprising:
[Present invention 1051]
The method of any of the inventions 1045-1050, wherein the administering step comprises applying microneedles to the subject.
[Invention 1052]
A method of enhancing the effectiveness of anticancer therapy in a subject in need thereof, the method comprising:
an effective amount of the immunotherapeutic construct of any of the inventions 1001-1032 or the composition of the invention 1033;
at least one anticancer drug and
the process of administering to a subject in need of it
The method described above.
[Present invention 1053]
1052. The method of the invention 1052, wherein the anti-cancer agent is a chemotherapeutic agent or a targeted therapy agent.
[Invention 1054]
1. A method of enhancing the effectiveness of checkpoint blockade immunotherapy in a subject diagnosed with a neoplasm, the method comprising:
an effective amount of the immunotherapeutic construct of any of the inventions 1001-1032 or the composition of the invention 1033;
at least one immune checkpoint inhibitor and
the process of administering to a subject in need of it
The method described above.
[Present invention 1055]
A method of enhancing the effectiveness of radiation therapy in a subject diagnosed with a neoplasm, the method comprising:
an effective amount of the immunotherapeutic construct of any of the inventions 1001-1032 or the composition of the invention 1033;
at least one radiation therapy and
the process of administering to a subject in need of it
The method described above.
[Invention 1056]
The method of any of the inventions 1052-1055, wherein the immunotherapeutic construct or composition and the anticancer therapy are administered sequentially or simultaneously.
[Present invention 1057]
The method of any one of inventions 1052-1056, wherein the subject is a mammal.
[Invention 1058]
1057. The method of the invention, wherein the mammal is a human.
[Invention 1059]
The immunotherapeutic construct of any of the invention 1001-1032;
at least one anticancer drug and
Including the kit.
[Invention 1060]
The kit of the present invention 1059, wherein the anticancer agent is a chemotherapeutic agent, a targeted therapy agent, or an immune checkpoint inhibitor.

Claims (50)

送達ビヒクルと、
腫瘍抗原放出を引き起こすおよび/または免疫抑制性腫瘍微小環境を調節する少なくとも1つの治療剤と、
少なくとも1つのアジュバントと
を含む、免疫療法構築物であって、
治療剤とアジュバントが、送達ビヒクル内に負荷されている、送達ビヒクルの表面に付着されている、送達ビヒクルに結合されている、送達ビヒクル内に封入されている、または送達ビヒクル内に含有されている、および
腫瘍特異的抗原またはオボアルブミンを含まない、
前記免疫療法構築物。 a delivery vehicle;
at least one therapeutic agent that causes tumor antigen release and/or modulates an immunosuppressive tumor microenvironment;
with at least one adjuvant
An immunotherapy construct comprising :
The therapeutic agent and adjuvant are loaded into, attached to, bound to, encapsulated within, or contained within the delivery vehicle. are, and
Contains no tumor-specific antigens or ovalbumin,
Said immunotherapeutic construct. 送達ビヒクルが、リポソーム、脂質系粒子、ポリマー粒子、無機粒子、またはそれらのハイブリッドを含む、請求項1記載の免疫療法構築物。 2. The immunotherapeutic construct of claim 1, wherein the delivery vehicle comprises a liposome, a lipid-based particle, a polymeric particle, an inorganic particle, or a hybrid thereof. 送達ビヒクルが、リポソーム、脂質系粒子、ポリマー粒子、無機粒子、またはポリマーもしくは脂質で被覆された無機粒子である、請求項2記載の免疫療法構築物。 3. The immunotherapeutic construct of claim 2, wherein the delivery vehicle is a liposome, a lipid-based particle, a polymeric particle, an inorganic particle, or an inorganic particle coated with a polymer or lipid. 送達ビヒクルが、無機粒子であり、メソポーラスシリカ、金、アルミニウム、銀、酸化鉄、リン酸カルシウム、抗酸化剤粒子、または酸化セリウムを含む抗酸化剤粒子のうちの1つまたは複数を含む、請求項3記載の免疫療法構築物。 3. The delivery vehicle is an inorganic particle and comprises one or more of mesoporous silica, gold, aluminum, silver, iron oxide, calcium phosphate , antioxidant particles , or antioxidant particles comprising cerium oxide. Immunotherapy constructs described. 送達ビヒクルが、メソポーラスシリカ粒子を含む、請求項4記載の免疫療法構築物。 5. The immunotherapeutic construct of claim 4, wherein the delivery vehicle comprises mesoporous silica particles. 送達ビヒクルが、フラーレン、エンドヘドラル金属フラーレン（endohedral metallofullerene）、三金属窒化物鋳型エンドヘドラル金属フラーレン、単層カーボンナノチューブおよび多層カーボンナノチューブ、分枝状カーボンナノチューブおよび樹枝状カーボンナノチューブ、金ナノロッド、銀ナノロッド、単層ホウ素/ナイトレートナノチューブおよび多層ホウ素/ナイトレートナノチューブ、カーボンナノチューブピーポッド、カーボンナノホーン、カーボンナノホーンピーポッド、リポソーム、ナノシェル、デンドリマー、マイクロ粒子、量子ドット、超常磁性ナノ粒子、ナノロッド、セルロースナノ粒子、メソポーラスシリカ粒子、ケイ素、シリカマイクロスフェアおよびシリカナノスフェア、ポリマーマイクロスフェアおよびポリマーナノスフェア、シリカシェル、生分解性PLGAマイクロスフェアおよび生分解性PLGAナノスフェア、金粒子、酸化セリウム粒子、酸化亜鉛粒子、銀粒子、アルミニウム粒子、炭素粒子、鉄粒子、酸化鉄粒子、アジュバント粒子、ならびに/または修飾ミセルのうちの1つまたは複数を含む、請求項1記載の免疫療法構築物。 The delivery vehicle may include fullerenes, endohedral metallofullerenes, trimetal nitride-templated endohedral metallofullerenes, single- and multi-walled carbon nanotubes, branched and dendritic carbon nanotubes, gold nanorods, silver nanorods, single Layered and multi-walled boron/nitrate nanotubes, carbon nanotube peapods, carbon nanohorns, carbon nanohorn peapods, liposomes, nanoshells, dendrimers, microparticles, quantum dots, superparamagnetic nanoparticles, nanorods, cellulose nanoparticles, mesoporous silica Particles, silicon, silica microspheres and silica nanospheres, polymer microspheres and polymer nanospheres, silica shells, biodegradable PLGA microspheres and biodegradable PLGA nanospheres, gold particles, cerium oxide particles, zinc oxide particles, silver particles, aluminum particles 2. The immunotherapeutic construct of claim 1, comprising one or more of , carbon particles, iron particles, iron oxide particles, adjuvant particles, and/or modified micelles. 送達ビヒクルが、PLGA、PLL、デキストラン、デンドリマー、ポリアルギニン、PEG、PEI、またはキトサンのうちの1つまたは複数を含むポリマー粒子である、請求項1～6のいずれか一項記載の免疫療法構築物。 The immunotherapeutic construct according to any one of claims 1 to 6 , wherein the delivery vehicle is a polymeric particle comprising one or more of PLGA, PLL, dextran, dendrimer, polyarginine, PEG, PEI, or chitosan. . 5nm～999nm、5nm～200nm、または1ミクロン～1000ミクロンの流体力学的サイズを有する、請求項1～7のいずれか一項記載の免疫療法構築物。 An immunotherapeutic construct according to any one of claims 1 to 7 , having a hydrodynamic size of 5 nm to 999 nm , 5 nm to 200 nm, or 1 micron to 1000 microns . 送達ビヒクルが、約5～約200nmのサイズを有するメソポーラスシリカナノ粒子を含む、請求項5記載の免疫療法構築物。 6. The immunotherapeutic construct of claim 5 , wherein the delivery vehicle comprises mesoporous silica nanoparticles having a size of about 5 to about 200 nm. メソポーラスシリカナノ粒子が、架橋されたポリエチレンイミンおよびポリエチレングリコールで被覆されている、請求項9記載の免疫療法構築物。 10. The immunotherapeutic construct of claim 9 , wherein the mesoporous silica nanoparticles are coated with cross-linked polyethyleneimine and polyethylene glycol. 少なくとも1つの治療剤が、siRNA、miRNA、アンチセンスオリゴヌクレオチド、mRNA、DNA、sgRNA（CRISPR-cas9エレメント）、オリゴヌクレオチド、ポリヌクレオチド、ペプチド、タンパク質、化学療法薬、毒素、抗酸化剤、小分子阻害剤、抗体、または放射線療法剤を含む、請求項1～10のいずれか一項記載の免疫療法構築物。 At least one therapeutic agent is siRNA, miRNA, antisense oligonucleotide, mRNA, DNA, sgRNA (CRISPR-cas9 element), oligonucleotide, polynucleotide, peptide, protein, chemotherapeutic drug, toxin, antioxidant, small molecule An immunotherapeutic construct according to any one of claims 1 to 10 , comprising an inhibitor, an antibody, or a radiotherapeutic agent. 少なくとも1つの治療剤が、siRNA、miRNA、アンチセンスオリゴヌクレオチド、mRNA、またはDNAを含む、請求項11記載の免疫療法構築物。 12. The immunotherapeutic construct of claim 11 , wherein the at least one therapeutic agent comprises siRNA, miRNA, antisense oligonucleotide, mRNA, or DNA. 少なくとも1つの治療剤が、siRNAを含む、請求項12記載の免疫療法構築物。 13. The immunotherapeutic construct of claim 12 , wherein at least one therapeutic agent comprises siRNA. 少なくとも1つの治療剤が、STAT3、CD39、CD73、TGF-β、PD-L1、PD1、CTLA4、MIF、PLK1、HIF、NOX1～4、HER2、EGFR、BCL2、AKT1、HIF1-α、AR、MYC、BRAF、BRAF V600E、またはMTDHの発現または活性を阻害するsiRNAを含む、請求項13記載の免疫療法構築物。 At least one therapeutic agent is STAT3, CD39, CD73, TGF-β, PD-L1, PD1, CTLA4, MIF, PLK1, HIF, NOX1-4, HER2, EGFR, BCL2, AKT1, HIF1-α , AR, MYC 14. The immunotherapeutic construct of claim 13 , comprising siRNA that inhibits the expression or activity of , BRAF, BRAF V600E, or MTDH. 少なくとも1つの治療剤が、STAT3の発現または活性を阻害するsiRNAを含む、請求項13または14記載の免疫療法構築物。 15. The immunotherapeutic construct of claim 13 or 14 , wherein the at least one therapeutic agent comprises siRNA that inhibits STAT3 expression or activity. 少なくとも1つの治療剤が、HER2の発現または活性を阻害するsiRNAを含む、請求項13～15のいずれか一項記載の免疫療法構築物。 16. The immunotherapeutic construct of any one of claims 13-15 , wherein at least one therapeutic agent comprises siRNA that inhibits HER2 expression or activity. 少なくとも1つの治療剤が、STAT3、CD39、CD73、TGF-β、PD-L1、PD1、CTLA4、MIF、PLK1、HIF、NOX1～4、HER2、EGFR、BCL2、AKT1、HIF1-α、AR、MYC、BRAF、BRAF V600E、RAS、PI3K、またはMTDHの発現または活性を阻害する、請求項1～10のいずれか一項記載の免疫療法構築物。 At least one therapeutic agent is STAT3, CD39, CD73, TGF-β, PD-L1, PD1, CTLA4, MIF, PLK1, HIF, NOX1-4, HER2, EGFR, BCL2, AKT1, HIF1-α , AR, MYC , BRAF, BRAF V600E, RAS, PI3K, or MTDH expression or activity. 少なくとも1つの治療剤が、抗生物質、植物アルカロイド、PLK1阻害剤、分裂期キナーゼ阻害剤、免疫チェックポイント阻害剤、白金系化学療法剤、HER2小分子阻害剤、抗EGFR抗体、抗HER2抗体、ボラセルチブ、セツキシマブ、トラスツズマブ、抗PD-L1抗体、抗PD1抗体、抗CTLA4抗体、ドセタキセル、パクリタキセル、ドキソルビシン、ミトキサントロン、カバジタキセル、インターロイキン、IL-2、IL-12、IL-15、またはIL-15/IL-15Ra複合体から選択される1つまたは複数の抗癌剤を含む、請求項1～17のいずれか一項記載の免疫療法構築物。 At least one therapeutic agent is an antibiotic, a plant alkaloid, a PLK1 inhibitor, a mitotic kinase inhibitor, an immune checkpoint inhibitor, a platinum-based chemotherapeutic agent, a HER2 small molecule inhibitor, an anti-EGFR antibody , an anti-HER2 antibody , volasertib , cetuximab, trastuzumab, anti-PD-L1 antibody, anti-PD1 antibody, anti-CTLA4 antibody, docetaxel, paclitaxel, doxorubicin, mitoxantrone, cabazitaxel, interleukin, IL-2, IL-12, IL-15, or IL-15 18. Immunotherapy construct according to any one of claims 1 to 17 , comprising one or more anti-cancer agents selected from /IL-15Ra complex . アジュバントが、免疫刺激活性を有し、CpGオリゴヌクレオチド、CpG配列を含むDNA TLRアゴニスト、非CpG DNA TLRアゴニスト、RNA TLRアゴニスト、アルミニウム塩、抗CD40抗体、融合タンパク質、サイトカイン、小分子TLRアゴニスト、油系アジュバントもしくは界面活性剤系アジュバント、リポ多糖、植物抽出物、もしくはそれらの誘導体；またはイミキモド、レシキモド、ガーディキモド、ポリI:C、ポリICLC、dSLIM、もしくはEnanDIMのうちの1つまたは複数を含む、請求項1～18のいずれか一項記載の免疫療法構築物。 The adjuvant has immunostimulatory activity, CpG oligonucleotides, DNA TLR agonists containing CpG sequences, non-CpG DNA TLR agonists, RNA TLR agonists, aluminum salts, anti-CD40 antibodies, fusion proteins, cytokines, small molecule TLR agonists, oils. or one or more of imiquimod, resiquimod, gardikimod , poly I:C, poly ICLC, dSLIM, or EnanDIM; An immunotherapeutic construct according to any one of claims 1 to 18 , comprising: アジュバントが、免疫アジュバントとして機能するサイトカインである、請求項1～19のいずれか一項記載の免疫療法構築物。 Immunotherapy construct according to any one of claims 1 to 19 , wherein the adjuvant is a cytokine that functions as an immune adjuvant . サイトカインが、IL-2である、請求項20記載の免疫療法構築物。21. The immunotherapeutic construct of claim 20, wherein the cytokine is IL-2. PLK1 siRNAおよび抗EGFR抗体を含む、請求項1～19のいずれか一項記載の免疫療法構築物。Immunotherapy construct according to any one of claims 1 to 19, comprising PLK1 siRNA and an anti-EGFR antibody. 請求項1～22のいずれか一項記載の免疫療法構築物と、
少なくとも1つの薬学的に許容される担体、賦形剤、希釈剤、またはそれらの混合物と
を含む、組成物。 an immunotherapeutic construct according to any one of claims 1 to 22 ;
and at least one pharmaceutically acceptable carrier, excipient, diluent, or mixture thereof. 癌を有する対象に、免疫療法構築物または組成物の有効量を投与することにより、癌を処置するための、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物。 An immunotherapeutic construct according to any one of claims 1 to 22 or according to claim 23 for treating cancer by administering an effective amount of the immunotherapeutic construct or composition to a subject having cancer. composition . 対象が哺乳動物である、請求項24記載の免疫療法構築物または組成物。 25. The immunotherapeutic construct or composition of claim 24 , wherein the subject is a mammal. 哺乳動物がヒトである、請求項25記載の免疫療法構築物または組成物。 26. The immunotherapeutic construct or composition of claim 25 , wherein the mammal is a human. 癌の症状を示す細胞と、免疫療法構築物または組成物の治療有効量とを接触させることにより、該細胞を処置するための、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物。 An immunotherapeutic construct or composition according to any one of claims 1 to 22 for treating cells exhibiting symptoms of cancer by contacting the cells with a therapeutically effective amount of the immunotherapeutic construct or composition . 24. The composition of claim 23 . 癌もしくは別の過剰増殖性疾患を有すると診断された対象、そのような疾患を発症するリスクが高いと診断された対象、または癌もしくは別の過剰増殖性障害の症状を示す対象から得られた細胞を処置する方法であって、該細胞と、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物の治療有効量とを接触させる工程を含む、前記方法。 Obtained from a subject who has been diagnosed with cancer or another hyperproliferative disorder, who has been diagnosed with an increased risk of developing such a disease, or who exhibits symptoms of cancer or another hyperproliferative disorder . 24. A method of treating cells that have been treated with immunotherapy comprising the step of contacting said cells with a therapeutically effective amount of an immunotherapeutic construct according to any one of claims 1 to 22 or a composition according to claim 23 . Said method. 癌もしくは別の過剰増殖性疾患を有すると診断された対象、そのような疾患を発症するリスクが高いと診断された対象、癌もしくは別の過剰増殖性障害の症状を示す対象、または健常ドナーから得られた細胞を処置する方法であって、該細胞と、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物の治療有効量とをエクスビボで接触させる工程を含む、前記方法。 A subject who has been diagnosed with cancer or another hyperproliferative disorder, who has been diagnosed with an increased risk of developing such a disease, who exhibits symptoms of cancer or another hyperproliferative disorder, or who is otherwise healthy . 24. A method of treating cells obtained from a donor , comprising contacting the cells ex vivo with a therapeutically effective amount of an immunotherapeutic construct according to any one of claims 1 to 22 or a composition according to claim 23 . The method, comprising the step of: 細胞が癌細胞である、請求項28または29記載の方法。 30. The method according to claim 28 or 29 , wherein the cells are cancer cells. 細胞が癌細胞ではない、請求項28または29記載の方法。 30. The method of claim 28 or 29 , wherein the cells are not cancer cells. 細胞が免疫細胞である、請求項31記載の方法。 32. The method of claim 31 , wherein the cell is an immune cell. 細胞が不死化される、請求項28または29記載の方法。 30. The method of claim 28 or 29 , wherein the cells are immortalized. 少なくとも1つの処置された細胞を、癌もしくは別の過剰増殖性疾患と診断された対象または癌の症状を示す対象に戻すように投与するための、請求項27記載の免疫療法構築物または組成物。 28. The immunotherapeutic construct or composition of claim 27 for administering the at least one treated cell back to a subject diagnosed with cancer or another hyperproliferative disease or exhibiting symptoms of cancer . 組成物の有効量を、過剰増殖性疾患もしくは過剰増殖性病態を有すると診断された対象、またはそのような疾患もしくは病態を発症するリスクが高いと診断された対象に投与することにより、該対象を処置するための、請求項23記載の組成物。 By administering an effective amount of the composition to a subject who has been diagnosed with a hyperproliferative disease or condition , or who has been diagnosed with an increased risk of developing such a disease or condition. 24. The composition of claim 23 for treating. 対象が哺乳動物である、請求項35記載の組成物。 36. The composition of claim 35 , wherein the subject is a mammal. 哺乳動物がヒトである、請求項36記載の組成物。 37. The composition of claim 36 , wherein the mammal is a human. 過剰増殖性疾患または過剰増殖性病態が、癌、前癌、または癌転移のうちの1つまたは複数を含む、請求項35～37のいずれか一項記載の組成物。 38. The composition of any one of claims 35-37 , wherein the hyperproliferative disease or condition comprises one or more of cancer, pre-cancer, or cancer metastasis. 過剰増殖性疾患が、黒色腫、肺癌、乳癌、膵癌、脳癌、前立腺癌、頭頸部癌、腎癌、結腸直腸癌、リンパ腫、胃癌、結腸癌、肝癌、肉腫、または稀な癌のうちの1つまたは複数を含む、請求項35～38のいずれか一項記載の組成物。 The hyperproliferative disease is melanoma, lung cancer, breast cancer, pancreatic cancer, brain cancer, prostate cancer, head and neck cancer, kidney cancer, colorectal cancer, lymphoma, stomach cancer, colon cancer, liver cancer, sarcoma, or rare cancers. 39. A composition according to any one of claims 35 to 38 , comprising one or more. 投与が、
対象の腫瘍への、もしくは対象の腫瘍での注射、
対象の腫瘍への、もしくは対象の腫瘍での局所的な注入、
対象における全身注射、
対象における全身注入、または
対象への局所適用
を含む、請求項35～39のいずれか一項記載の組成物。 The administration is
injection into or at the target tumor;
local injection into or at the tumor of interest;
systemic injection in the subject,
40. The composition of any one of claims 35-39 , comprising systemic injection in a subject, or topical application to a subject. 投与が、対象へのマイクロニードル適用を含む、請求項35～40のいずれか一項記載の組成物。 41. The composition of any one of claims 35-40 , wherein the administering comprises microneedle application to the subject. それを必要とする対象において抗癌療法の効果を増強するための、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物であって、該免疫療法構築物または該組成物の有効量を、抗癌療法としての少なくとも1つの抗癌剤と組み合わせて該対象に投与することにより抗癌療法の効果を増強する、前記免疫療法構築物または前記組成物。 24. An immunotherapeutic construct according to any one of claims 1 to 22 or a composition according to claim 23 for enhancing the efficacy of anti-cancer therapy in a subject in need thereof, comprising: Said immunotherapeutic construct or said composition , wherein said immunotherapeutic construct or said composition enhances the effect of anti-cancer therapy by administering to said subject an effective amount of said composition in combination with at least one anti-cancer agent as anti-cancer therapy . 抗癌剤が、化学療法剤または標的療法剤である、請求項42記載の免疫療法構築物または組成物。 43. The immunotherapeutic construct or composition of claim 42 , wherein the anti-cancer agent is a chemotherapeutic agent or a targeted therapy agent. 新生物を有すると診断された対象においてチェックポイント遮断免疫療法の効果を増強するための、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物であって、該免疫療法構築物または該組成物の有効量を、抗癌療法としての少なくとも1つの免疫チェックポイント阻害剤と組み合わせて、それを必要とする対象に投与することによりチェックポイント遮断免疫療法の効果を増強する、前記免疫療法構築物または前記組成物。 24. An immunotherapeutic construct according to any one of claims 1 to 22 or a composition according to claim 23 for enhancing the effectiveness of checkpoint blockade immunotherapy in a subject diagnosed with a neoplasm , comprising: Enhance the effectiveness of checkpoint blockade immunotherapy by administering an effective amount of the immunotherapy construct or composition in combination with at least one immune checkpoint inhibitor as an anti-cancer therapy to a subject in need thereof. said immunotherapeutic construct or said composition . 新生物を有すると診断された対象において放射線療法の効果を増強するための、請求項1～22のいずれか一項記載の免疫療法構築物または請求項23記載の組成物であって、該免疫療法構築物または該組成物の有効量を、抗癌療法としての少なくとも1つの放射線療法と組み合わせて、それを必要とする対象に投与することにより放射線療法の効果を増強する、前記免疫療法構築物または前記組成物。 24. An immunotherapy construct according to any one of claims 1 to 22 or a composition according to claim 23 for enhancing the effect of radiotherapy in a subject diagnosed with a neoplasm , said immunotherapy Said immunotherapeutic construct or composition, wherein said immunotherapeutic construct or said composition enhances the effect of radiotherapy by administering an effective amount of said construct or said composition in combination with at least one radiotherapy as an anti-cancer therapy to a subject in need thereof. Things . 免疫療法構築物または組成物と抗癌療法とが、連続的にまたは同時に投与される、請求項42～45のいずれか一項記載の免疫療法構築物または組成物。 46. The immunotherapeutic construct or composition of any one of claims 42-45 , wherein the immunotherapeutic construct or composition and the anti-cancer therapy are administered sequentially or simultaneously. 対象が哺乳動物である、請求項42～46のいずれか一項記載の免疫療法構築物または組成物。 47. An immunotherapeutic construct or composition according to any one of claims 42 to 46 , wherein the subject is a mammal. 哺乳動物がヒトである、請求項47記載の免疫療法構築物または組成物。 48. The immunotherapeutic construct or composition of claim 47 , wherein the mammal is a human. 請求項1～22のいずれか一項記載の免疫療法構築物または請求項23の組成物と、少なくとも1つの抗癌剤とを含む、キット。 A kit comprising an immunotherapeutic construct according to any one of claims 1 to 22 or a composition according to claim 23 and at least one anti-cancer agent. 抗癌剤が、化学療法剤、標的療法剤、または免疫チェックポイント阻害剤である、請求項49記載のキット。 50. The kit according to claim 49 , wherein the anticancer agent is a chemotherapeutic agent, a targeted therapy agent, or an immune checkpoint inhibitor.
JP2022502029A 2019-07-12 2020-07-13 Immunotherapy Constructs and Methods of Their Use Pending JP2022540867A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873762P 2019-07-12 2019-07-12
US62/873,762 2019-07-12
PCT/US2020/041844 WO2021011496A1 (en) 2019-07-12 2020-07-13 Immunotherapeutic constructs and methods of their use

Publications (2)

Publication Number Publication Date
JP2022540867A JP2022540867A (en) 2022-09-20
JPWO2021011496A5 true JPWO2021011496A5 (en) 2023-10-23

Family

ID=74102552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502029A Pending JP2022540867A (en) 2019-07-12 2020-07-13 Immunotherapy Constructs and Methods of Their Use

Country Status (8)

Country Link
US (3) US20220249389A1 (en)
EP (1) EP3999111A4 (en)
JP (1) JP2022540867A (en)
KR (1) KR20220035160A (en)
CN (1) CN114096274A (en)
AU (1) AU2020315590A1 (en)
CA (1) CA3139722A1 (en)
MX (1) MX2022000544A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996750A4 (en) 2019-07-12 2024-01-03 Univ Oregon Health & Science Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US20240066119A1 (en) * 2021-01-13 2024-02-29 University Of Maryland, College Park Methods and platforms for eliciting an immune response in the treatment of cancer and compositions and vaccines relating thereto
CN115060777B (en) * 2022-07-08 2023-06-23 江苏理工学院 Rate electrochemical aptamer sensor for simultaneously detecting malathion and omethoate, and preparation method and application thereof
WO2024049734A1 (en) * 2022-08-29 2024-03-07 Celanese Eva Performance Polymers Llc Implantable device for intratumorally administering a therapeutic agent
CN117085001B (en) * 2023-10-18 2024-02-13 中国医学科学院药用植物研究所 Preparation method and application of dual-targeting core-shell structure nano drug-loaded particles
CN117731616A (en) * 2023-12-18 2024-03-22 中山大学孙逸仙纪念医院 Glutathione response nanomaterial loaded with tumor suppressor gene siRNA

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US6740336B2 (en) 2002-10-04 2004-05-25 Mirus Corporation Process for generating multilayered particles
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
US20060293396A1 (en) 2005-01-14 2006-12-28 Eastman Kodak Company Amine polymer-modified nanoparticulate carriers
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2008094254A2 (en) * 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
JP5911799B2 (en) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ Immunomodulatory composition comprising a polymer matrix and an oil phase
US20120207795A1 (en) * 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103958519A (en) 2011-07-19 2014-07-30 爱达荷州大学 Embodiments of a probe and method for targeting nucleic acids
CA2820236C (en) 2012-06-15 2022-07-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system
EA034242B1 (en) * 2013-01-25 2020-01-21 Нанобиотикс Method for inducing reduction of tumor size in a human subject having cancer
EP3046547A4 (en) 2013-09-18 2017-05-24 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
RU2672055C2 (en) * 2013-11-01 2018-11-09 Йейл Юниверсити Modular particles for immunotherapy
WO2015077657A2 (en) 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof
CA2943075C (en) * 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP6685924B2 (en) 2014-04-11 2020-04-22 メディミューン，エルエルシー Conjugate compounds containing cysteine engineered antibodies
WO2016013751A1 (en) 2014-07-22 2016-01-28 주식회사 레모넥스 Composition for delivering bioactive material or protein, and use thereof
US20160090603A1 (en) 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
WO2016149378A1 (en) 2015-03-16 2016-09-22 Pdx Pharmaceuticals, Llc Cross-linked polymer modified nanoparticles
BR112017020491A2 (en) 2015-03-25 2018-07-17 The Regents Of The University Of Michigan compositions and methods for delivery of biomacromolecule agents.
DK3326641T3 (en) * 2015-04-22 2019-09-30 Curevac Ag RNA-Containing Composition for the Treatment of Tumor Diseases
EP3303598A4 (en) 2015-05-26 2019-01-23 Ramot at Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017040660A1 (en) 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
MX2018007406A (en) 2015-12-16 2018-08-15 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments.
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
US11110168B2 (en) * 2016-03-15 2021-09-07 North Carolina State University Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
AU2017266929B2 (en) 2016-05-18 2023-05-11 Modernatx, Inc. Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
BR112019021520A2 (en) * 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotide, compound, immunomodulatory polynucleotide, composition, conjugate, method to modulate a receptor, method of treating a tumor, method of treating cancer, method of treating a tumor, method of preventing cancer, method of inducing an immune response
US11554178B2 (en) * 2017-06-30 2023-01-17 City Of Hope Compositions and methods of modulating macrophage activity
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
US20190374479A1 (en) 2018-06-12 2019-12-12 The Brigham And Women's Hospital, Inc. Particles for delivery of biomolecules
EP3996750A4 (en) * 2019-07-12 2024-01-03 Univ Oregon Health & Science Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor

Similar Documents

Publication Publication Date Title
Hosseini et al. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy
Jo et al. Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy
Yan et al. Current applications and future prospects of nanotechnology in cancer immunotherapy
Ma et al. Extracellular vesicles: an emerging nanoplatform for cancer therapy
Duwa et al. Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells
WO2011130753A2 (en) Functionalized nano- and micro-materials for medical therapies
Chowdhury et al. Bioactive nanotherapeutic trends to combat triple negative breast cancer
Alhaj-Suliman et al. Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
Attama et al. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade
Radhakrishnan et al. The emergence of nanoporous materials in lung cancer therapy
Guo et al. Rational nanocarrier design towards clinical translation of cancer nanotherapy
US11034773B2 (en) Methods and materials for treating cancer
Dacoba et al. Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Kaur et al. Cancer treatment therapies: traditional to modern approaches to combat cancers
Qiu et al. Nanobiotechnology-based treatment strategies for malignant relapsed glioma
Küçüktürkmen et al. Mesoporous silica nanoparticles as carriers for biomolecules in cancer therapy
Carney et al. Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases
Argenziano et al. Exploring chitosan-shelled nanobubbles to improve HER2+ immunotherapy via dendritic cell targeting
JPWO2021011496A5 (en)
Elsewedy et al. A review article on the basic concepts of drug delivery systems as targeting agents
Behl et al. Nano-based drug delivery of anticancer chemotherapeutic drugs targeting breast cancer
Kulkarni et al. Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies
Jin et al. Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
Dang et al. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Smiley et al. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance